| abstract |
Claim 1: A method of treating a patient diagnosed with platinum-resistant ovarian cancer that includes administering to said patient an effective amount of an anti-VEGF antibody and a chemotherapeutic agent, wherein said patient received two or less prior anticancer regimens. , in which said treatment prolongs the survival time free of average progression of the patient compared to a patient with platinum resistant ovarian cancer who only receives said chemotherapeutic. Claim 7: The method of claim 1, wherein said chemotherapeutic is selected from a group that includes paclitaxel, topotecan or a pegylated liposomal doxorubicin (PLD). Claim 13: The method of claim 1, wherein said anti-VEGF antibody is bevacizumab. Claim 14: The method of claim 1, wherein said anti-VEGF antibody includes a variable heavy chain (VH) and a variable light chain (VL), wherein said VH has an amino acid sequence with the ID of Sec. No. 2 and said VL has an amino acid sequence with the ID of Sec. No. 1. |